

In the Claims

Please cancel Claims 2-4 and 15.

Please also cancel Claims 1, 5, 6, 8, and 14.

Please add new Claims 34-38 as follows:

8 9 34. A substantially non-irritating
B B pharmaceutical formulation for topical and/or transdermal
B B administration of the agent 1-isobutyl-1H-imidazo[4,5-
B B c]quinolin-4-amine, which formulation comprises:

B 89 (a) a therapeutically effective amount of 1
B B isobutyl-1H-imidazo[4,5-c]quinolin-4-amine; and
B B (b) a pharmaceutically acceptable vehicle for
B B said 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine, which
B B vehicle comprises isostearic acid in an amount of about 3
B B percent to about 45 percent by weight based on the total
B B weight of said formulation, said formulation being further
B B characterized in that, when tested according to the
B B hairless mouse skin model the formulation provides a
B B penetration of the agent of at least about 10 percent of
B B the total amount of the agent contained in the formulation
B B in 24 hours.

B B 35. A formulation according to claim 34 wherein
B B said 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine is
B B present in an amount of about 0.5 percent to about 9
B B percent by weight based on the total weight of said
B B formulation.

B 36. A formulation according to claim 34 in the
B form of a cream, comprising an oil phase and a water phase
B in admixture, said oil phase comprising:

B 89 (a) said 1-isobutyl-1H-imidazo[4,5-c]quinolin-
B 4-amine;
B (b) said isostearic acid;
B (c) one or more emollients present in a total
B amount of about 5 percent to about 30 percent by weight
B based on the total weight of said formulation; and